Humacyte, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Humacyte, Inc. (HUMA) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $17.70 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-12
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $17.70M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $21.00M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $23.50M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $26.80M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $17.70M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $21.00M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $23.50M 10-K · filed 2026-03-27 |
| 2025-09-30 | $26.80M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $30.30M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $33.40M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $18.10M 10-K · filed 2025-03-31 |
| 2024-09-30 | $19.30M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $20.40M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $16.50M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $17.90M 10-K · filed 2024-03-28 |
| 2023-09-30 | $8.50M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $10.30M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $11.60M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $13.30M 10-K · filed 2023-03-24 |
| 2022-09-30 | $10.23M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $10.97M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $10.58M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $13.35M 10-Q · filed 2022-11-10 |
| 2021-09-30 | $12.48M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $5.79M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |